107 studies found for:    Open Studies | "Nephritis"
Show Display Options
Rank Status Study
21 Recruiting Immune System Related Kidney Disease
Conditions: Glomerulonephritis;   Lupus Nephritis;   Membranous Glomerulonephritis;   Nephritis;   Nephrotic Syndrome
Intervention:
22 Recruiting AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin
Condition: Lupus Nephritis
Interventions: Drug: Voclosporin High Dose;   Drug: Voclosporin Low Dose;   Drug: Placebo
23 Recruiting Hereditary Tubulointerstitial Nephritis
Conditions: Nephritis, Interstitial;   Chronic Renal Failure;   Gout;   Renal Cysts
Intervention: Other: Blood and urine sample collections
24 Recruiting Long-Term Study of Multi-target Therapy as Continuous Induction and Maintenance Treatment for Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: Tacrolimus+mycophenolate mofetil;   Drug: Azathioprine
25 Recruiting Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy
Condition: Lupus Nephritis
Intervention: Biological: Rituximab
26 Recruiting Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
Conditions: Kidney Diseases;   Kidney Failure, Chronic;   Diabetic Nephropathy;   Lupus Nephritis;   Glomerulonephritis, IGA
Intervention:
27 Not yet recruiting Phase Ib Study of SC Milatuzumab in SLE
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Discoid;   Lupus Erythematosus, Systemic;   Lupus Vasculitis, Central Nervous System;   Lupus Nephritis
Intervention: Drug: milatuzumab
28 Recruiting Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists
Conditions: Hospitalized Cases of Angioneurotic Oedema;   Pneumonia;   Gastroenteritis;   Failure to Thrive;   Seizures;   Acute Interstitial Nephritis and Thrombocytopenia
Intervention:
29 Unknown  Cyclophosphamide in Lupus Nephritis
Condition: Systemic Lupus Erythematosus
Intervention:
30 Recruiting The Effect of Calcitriol on Progress and Activity of Lupus Nephritis
Condition: Systemic Lupus Erythematosus
Interventions: Drug: calcitriol;   Drug: placebo
31 Recruiting ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis
Condition: SLE Glomerulonephritis Syndrome, WHO Class V
Intervention: Drug: Acthar gel
32 Not yet recruiting CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Blisibimod;   Drug: Placebo
33 Recruiting Alport Syndrome Treatments and Outcomes Registry
Condition: Alport Syndrome
Intervention:
34 Recruiting ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Condition: Alport Syndrome Patients With Measured GFR Between 30-75 ml/Min
Intervention:
35 Recruiting Treatment of Resistant Hypertension by Renal Sympathetic Denervation in Patients Undergoing Dialysis Therapy
Condition: Hypertension Secondary to Renal Disease
Intervention: Procedure: Renal nerve denervation
36 Recruiting Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children
Conditions: Renal Insufficiency;   Infection
Interventions: Drug: Low-dose intravenous cyclophosphamide;   Drug: High-dose intravenous cyclophosphamide
37 Recruiting Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis
Conditions: Urinary Tract Infections;   Acute Pyelonephritis
Interventions: Drug: Finafloxacin 800 mg i.v. once daily;   Drug: Finafloxacin placebo i.v. once daily;   Drug: Finafloxacin 800 mg tablets (as four 200 mg tablets) once daily;   Drug: Finafloxacin placebo tablets (as four tablets) once daily;   Drug: Ciprofloxacin 400 mg i.v. two times daily;   Drug: Ciprofloxacin placebo i.v. two times daily;   Drug: Ciprofloxacin 500 mg oral (as two 250 mg capsules) two times daily;   Drug: Ciprofloxacin placebo oral (as two capsules each) two times daily
38 Recruiting Efficacy, Safety, Tolerability of Carbavance Compared to Best Available Therapy in Serious Infections Due to Carbapenem Resistant Enterobacteriaceae, in Adults
Conditions: Urinary Tract Infection Complicated;   Acute Pyelonephritis;   Hospital Acquired Bacterial Pneumonia;   Ventilator-associated Bacterial Pneumonia;   Bacteremia
Interventions: Drug: Carbavance;   Drug: Best Available Therapy
39 Recruiting Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
Conditions: Urinary Tract Infections;   Pyelonephritis
Interventions: Drug: MK-7655 250 mg;   Drug: MK-7655 125 mg;   Drug: imipenem/cilastatin 500 mg;   Drug: Placebo to MK-7655;   Drug: Ciprofloxacin
40 Not yet recruiting Antibiotic Treatment Versus no Therapy in Kidney Transplant Recipients With Asymptomatic Bacteriuria
Conditions: Asymptomatic Bacteriuria;   Pyelonephritis
Interventions: Drug: Antibiotic treatment;   Other: No treatment

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years